Most human cases were in direct contact with sick or dead birds, although no one involved in culling birds appears to have caught avian flu, WHO said. Avian flu is believed to have first jumped species from bird to man in 1997, when an outbreak of the disease caused by the A (H5N1) virus among birds triggered 18 human cases in Hong Kong Special Administrative Region of which 6 died.

WHO is conducting investigations into reports of H5N1 infection of domestic cats from a single household in Thailand. Fourteen out of the 15 cats have died, two of which have been reported infected with H5N1 by the Faculty of Veterinary Sciences at Thailand's Kasetsart University. According to WHO, confirmation of the virus in cats is not likely to enhance the present risks to human health.

First symptoms are fever, sore throat and cough, but the disease can lead also to hepatitis and even damage to the heart or kidneys.

For the latest information on avian flu, visit: http://www.who.int/csr/don/en/  

Fiona Fleck, Geneva

WHO refutes malaria malpractice allegations

WHO's Roll Back Malaria department has refuted allegations by an international group of 13 malaria researchers accusing WHO and the Global Fund to Fight, AIDS, Tuberculosis and Malaria (GFATM) of failing to promote available and effective malaria treatment in favour of ineffective but less-expensive drugs.

In a commentary published in the UK-based medical journal, the *Lancet* (2004;363:237–40), the critics led by Amir Attaran from London's Royal Institute of International Affairs, accuse the two agencies of blocking the introduction of highly effective artemisinin-based combination therapy (ACT) whilst continuing to approve grants for the conventional chloroquine and sulfadoxine-pyrimethamine in countries where these treatments are failing.

"For WHO and GFATM to provide chloroquine and sulfadoxine-pyrimethamine treatments … at least wastes precious international aid money and at most, kills patients who have malaria … at least tens of thousands of children die every year as a direct result," say the authors who compare the agencies with a "doctor who knowingly furnished treatments that failed perhaps 80% of the time, while witholding the alternatives as "too expensive"."

In a letter published in the *Lancet* (2004;363:397), Fatoumata Nafo-Traoré, Director of WHO's Roll Back Malaria Department, counters the accusations pointing out that "WHO has been making many of the same arguments for the past 3 years and fully supports the use of ACT."

Chloroquine and sulfadoxine-pyrimethamine have become increasingly ineffective due to the development of resistance in the deadly species of malaria, *Plasmodium falciparum*. Surveillance and clinical trial data in East Africa, for example, show that up to 64% of patients given chloroquine and 45% given sulfadoxine-pyrimethamine will fail treatment, and those figures are climbing, say the critics, Attaran et al.

They point out that artemisinins, on the other hand, which form the basis of ACT treatments, have been used in Chinese traditional medicine for 2000 years, with no observed resistance. "In studies done on nearly every continent, ACT successfully treats 90% or more of patients," say Attaran et al.

"The problem is cost: ACT is around ten times more expensive forcing most African countries to stick with conventional but increasingly useless malaria treatments. At the centre of the criticisms voiced in the *Lancet* is the continued approval by GFATM and WHO of funding for chloroquine and sulfadoxine-pyrimethamine for those countries which should be switching to ACT. "When those same countries seek financial aid from [GFATM] to purchase ACT, they are forcefully pressured out of it by governments such as the USA, whose aid officials say that ACT is too expensive … and WHO signs its approval," say Attaran et al.

According to WHO, one reason for poor countries' continuing applications to GFATM for the cheaper but less-effective anti-malaria drugs has been their uncertainty about GFATM — which has only been in existence for two years — as a source of long-term support. In other words, countries did not wish to switch to a more expensive drug only to see this income cut off a few years later. "Governments need to trust that sustainable funding from the Global Fund [GFATM] and other sources will be available before they can make the commitment — of up to US$ 2 per head per year — of switching to ACTs," said Nafo-Traoré.

Both agencies have also emphasized their roles as advisers or funders, insisting that antimalarial drug policy decisions must be led by national governments. However, as Nafo-Traoré points out, since 2001 “WHO has been actively promoting the use of ACT in countries before resistance to currently used monotherapies reaches an unacceptable level.” Since 2001, South Africa (KwaZulu Natal), Zambia, Zanzibar and Burundi have switched to ACTs as first-line treatment. By 2004 WHO expects at least 16 African countries to have adopted ACTs as first-line treatment. According to WHO, this timeframe is exceptionally short for such a far-reaching policy change. In addition, the threshold for the unacceptable level of therapeutic failures has been lowered from 25% to 15% and “countries will be strongly encouraged to modify their treatment policies accordingly,” says Nafo-Traoré.

Rather than refusing requests for suboptimal drugs which are based on current national policy, says Nafo-Traoré, GFATM has generally stipulated a policy review within a short period of time as a condition of funding. “As a result, WHO is able to work more effectively with decision-makers in countries to accelerate rational and feasible policy change.”

Malaria causes more than one million deaths worldwide every year, 90% of which occur in Africa, costing the continent more than US$ 12 billion every year.

West Africa prepares for the final battle against polio

Ten West African countries will begin a massive, synchronized polio immunization campaign on 23 February 2004 aimed at vaccinating 63 million children in the region in just a few days. The campaign comes just one month after Health Ministers gathered for an emergency meeting at WHO in Geneva calling for commitment to end polio transmission in 2004.

Political, religious and traditional leaders from Benin, Burkina Faso, Cameroon (due to begin vaccination on 20 February), Central African Republic, Chad (due to join the campaign in
March), Ghana, Niger, Nigeria, Côte d'Ivoire and Togo will come together to launch the campaign and tens of thousands of vaccinators will go house-to-house over three days to administer the vaccine directly to every child.

“After eight years of incredible collaboration and investment, Africa is standing on the verge of a well-deserved triumph in public health,” said Dr Ebrahim Samba, WHO Regional Director for the African Region.

However, hopes of a quick end to polio in Africa have been overshadowed by the recent polio outbreak in Nigeria. Until mid-2003, Nigeria was part of Africa’s polio success story, with only a few northern states remaining polio-endemic and the country’s capital, Lagos — Africa’s most densely populated city — polio-free for over two years. However, suspension of immunization campaigns in the northern state of Kano fuelled by unfounded rumours about the safety of polio vaccine led to an outbreak of the virus which then spread to the neighbouring polio-free countries of Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Ghana and Togo.

“The disease is now threatening to make a comeback, and the whole continent is on the brink of re-infection unless these campaigns stop the further spread of the virus,” said Samba.

“Before this new wave of cases, Africa had made the most rapid progress of any continent to secure a polio-free future for its children,” said Rima Salah, UNICEF’s Regional Director for West and Central Africa. "It would be an unspeakable tragedy to allow the virus to slip back now. National and community leaders must take a stand to stop the disease and ensure a victory over polio for the entire continent.”

The campaign to “Kick Polio Out of Africa,” launched by Nelson Mandela and other African leaders, has cut the number of children with paralysis caused by polio down from 205 cases per day in 1996 to just 388 a year in 2003.

Since its launch in 1988, the Global Polio Eradication Initiative, spearheaded by WHO, Rotary International, the US Centers for Disease Control and Prevention and UNICEF has seen the number of polio-endemic countries drop from 125 to just six — Afghanistan, Egypt, India, Niger, Nigeria and Pakistan.

Despite the resurgence of polio in West Africa which has put millions of children at risk, partners in the Global Polio Eradication Initiative remain hopeful that if the upcoming campaigns reach every child, polio transmission in Africa can still be stopped in 2004.

“Africa has proved it can stop polio — now its time to finish the job,” said Samba.

WHO issues guidelines for herbal medicines

WHO has released guidelines for ensuring the safety, efficacy and environmental sustainability of the US$ 60 billion a year herbal medicines market amidst an increasing number of reports indicating adverse health reactions caused by the misuse of medicinal plants.

The WHO guidelines on good agricultural and collection practices for medicinal plants, issued on 10 February 2004, are intended for national regulatory bodies and offer advice on cultivation and collection methods, site selection, climate and soil considerations and the correct identification of seeds and plants. They also offer guidance on post-harvest operations such as labelling and legal components including national and regional laws on quality standards, patent status and benefits sharing.

Representing an annual global market of US$ 60 billion every year, herbal medicines account for around 20% of the overall drug market.

According to WHO, up to 80% of the population in Africa depends on traditional medicinal herbs and other industrialized regions over 50% of total medicinal consumption. In Europe, North America and other industrialized regions over 50% of the population have used complementary or alternative medicine at least once.

“IT is not a binding guideline for any country, but it is a model or a sort of checklist which they can use to make their own national regulations,” said Hans Hogerzeil, acting Director of WHO’s Essential Drugs and Medicines department.

Although, 70 countries have a national regulation on herbal medicines, the legislative control of medicinal plants lacks structure due to differing definitions of medicinal herbs and products and diverse approaches to their licensing, dispensing, manufacturing and trading.

Hogerzeil described an enormous unregulated industry in which huge amounts of leaves and traditional medicines are being shipped from various exporting countries such as China, India and Pakistan to many other countries. “Somebody has to regulate that, at least their safety,” he said.

According to WHO, reports of patients experiencing negative health consequences caused by the use of herbal medicines are on the rise. These cases are usually linked to the poor quality of herbal medicines, the incorrect identification of plant species or inadequate labelling.

For example, ephedra or Ma Huang, traditionally used in China to treat respiratory congestion, was marketed in the states as a dietary aid. Overdosage led to at least a dozen deaths, heart attacks and strokes prompting the US Food and Drug Administration to issue a consumer alert in December 2003 on the safety of products containing ephedra.

The guidelines also address growing concerns over the potential threat to biodiversity posed by the booming herbal medicines market. Over-harvesting may lead to the extinction of endangered species and the destruction of national habitats and resources, warned WHO.

Oral diseases increasing in developing countries

Oral diseases such as tooth decay, gum disease and oral and pharyngeal cancers are still a problem in the developed world and have also become a threat to oral health in developing countries, says a new report released on 24 February 2004 by WHO’s Global Oral Health Programme.

According to the report (http://www.who.int/oral_health/publications/report03/en/), an estimated five billion people worldwide have experienced tooth decay. While it appears to be less severe in most African countries, the report states that tooth decay is expected to increase in many developing countries in Africa as a result of the growing consumption of sugars and inadequate exposure to fluorides.